Trials / Completed
CompletedNCT01839019
Safety and Tolerability Study With Single Ascending Doses of ODM-102
Safety, Tolerability and Pharmacokinetics of Single Escalating Doses of ODM-102: A Randomised, Double-blind, Placebo-controlled, Single Centre Study in Healthy Males
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety and tolerability of escalating single doses of ODM-102 in healthy volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ODM-102 | Single dose escalation |
| DRUG | Placebo for ODM-102 | Single dose escalation |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2013-06-01
- Completion
- 2013-08-01
- First posted
- 2013-04-24
- Last updated
- 2014-02-10
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT01839019. Inclusion in this directory is not an endorsement.